Spero Therapeutics, Inc.SPRONASDAQ
LOADING
|||
Cash Generation Expanding
Trending higher, above historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-23.44M
↑ 27% above average
Average (9y)
$-32.14M
Historical baseline
Range
High:$0.00
Low:$-86.03M
CAGR
+10.1%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-23.44M | +28.9% |
| 2023 | $-32.99M | -326.8% |
| 2022 | $-7.73M | - |
| 2021 | $0.00 | +100.0% |
| 2020 | $-86.03M | -70.9% |
| 2019 | $-50.33M | -19.7% |
| 2018 | $-42.06M | -7.5% |
| 2017 | $-39.14M | -31.4% |
| 2016 | $-29.79M | -202.7% |
| 2015 | $-9.84M | - |